Duoneb
From Wikipedia, the free encyclopedia
 |
It has been suggested that this article or section be merged into Ipratropium/salbutamol. (Discuss) |
| Image:TBD | |
|
Duoneb
|
|
| Systematic (IUPAC) name | |
| TBD | |
| Identifiers | |
| CAS number | |
| ATC code | TBD |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | (C13H21NO3)2 * H2SO4 + C20H30BrNO3 * H2O |
| Mol. mass | TBD g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Protein binding | TBD% |
| Metabolism | TBD |
| Half life | TBD hours |
| Excretion | TBD |
| Therapeutic considerations | |
| Pregnancy cat. |
TBD |
| Legal status |
TBD |
| Routes | Oral |
Duoneb is a combination of two bronchodilators, albuterol sulfate and ipratropium bromide. It is used to treat symptoms (ie, bronchospasms) in patients with lung disease (ie, chronic obstructive pulmonary disease or COPD). It is commonly administered using a nebulizer.
Duoneb is marketed by Dey, L.P. (Napa, California) under the brand name DuoNeb. It is available as a fluid (for use with a nebulizer).
Subject of recent Medicare and FDA controversy. FDA has moved for regulation of generic competition to commercial product whereas Medicare has moved to limit reimbursement of commercial product. Dispute resolution will have a material economic impact on leading respiratory service providers.
[edit] External links
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
